CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC

Key Points

• Needham reaffirmed its Buy rating on CRISPR Therapeutics and set an $82 price target, implying approximately 64% upside from the prior close.
• Analyst sentiment remains positive overall, with a consensus rating of Moderate Buy and an average price target of $65.75, though coverage includes neutral and sell ratings.
• CRISPR Therapeutics reported a quarterly loss of $1.15 per share and $12.67 million in revenue, missing analyst expectations for both measures; the stock opened at $49.99 and was trading down 2.8%.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $82.00 price objective on the stock. Needham & Company LLC's price objective suggests a potential upside of 64.03% from the company's previous close.

CRSP has been the subject of several other reports. UBS Group initiated coverage on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. They set a "neutral" rating and a $52.00 price target for the company. Citizens Jmp reiterated a "market outperform" rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. William Blair upgraded shares of CRISPR Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 23rd. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. Finally, HC Wainwright restated a "buy" rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $65.75.

CRISPR Therapeutics Trading Down 2.8%

CRSP opened at $49.99 on Tuesday. The firm has a market cap of $4.83 billion, a price-to-earnings ratio of -10.50 and a beta of 1.76. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics has a 12 month low of $44.12 and a 12 month high of $64.74. The stock has a fifty day moving average price of $54.00 and a 200-day moving average price of $52.89.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.11). CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The company had revenue of $12.67 million for the quarter, compared to the consensus estimate of $14.75 million. As a group, equities research analysts anticipate that CRISPR Therapeutics will post -4.44 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 47,837 shares of the firm's stock in a transaction on Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the completion of the transaction, the chief executive officer owned 311,899 shares of the company's stock, valued at $15,526,332.22. This trade represents a 13.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James R. Kasinger sold 1,040 shares of the firm's stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total transaction of $51,230.40. Following the transaction, the general counsel directly owned 95,857 shares of the company's stock, valued at approximately $4,721,915.82. This trade represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 93,558 shares of company stock worth $4,881,663 over the last ninety days. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of CRSP. Choreo LLC grew its position in CRISPR Therapeutics by 3.4% during the third quarter. Choreo LLC now owns 7,539 shares of the company's stock valued at $417,000 after buying an additional 247 shares during the period. Sterling Capital Management LLC increased its holdings in CRISPR Therapeutics by 15.5% in the third quarter. Sterling Capital Management LLC now owns 1,934 shares of the company's stock valued at $107,000 after buying an additional 260 shares in the last quarter. Interchange Capital Partners LLC raised its position in shares of CRISPR Therapeutics by 6.0% in the third quarter. Interchange Capital Partners LLC now owns 4,766 shares of the company's stock worth $264,000 after acquiring an additional 268 shares during the period. Versant Capital Management Inc raised its position in shares of CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company's stock worth $25,000 after acquiring an additional 296 shares during the period. Finally, Sunbelt Securities Inc. raised its position in shares of CRISPR Therapeutics by 4.5% in the first quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company's stock worth $373,000 after acquiring an additional 336 shares during the period. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: CASGEVY sales accelerated: Third-quarter CASGEVY revenue reached $99 million, up 30% sequentially and nearly sixfold from the year-earlier period. The therapy also received expanded pediatric approvals in the U.K., United Arab Emirates and Bahrain, improving its commercial opportunity. CRISPR Therapeutics Third-Quarter 2026 Results
• Positive Sentiment: Pipeline progress: The FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also expects to present CTX310 and zugo-cel clinical data at upcoming medical conferences and completed enrollment in a Phase 2 CTX611 trial. These developments could provide future catalysts. CRISPR Therapeutics Business Update
• Neutral Sentiment: Brokerage view remains a focus: Recent coverage reviews what analysts and brokerages think about CRSP, but the available report details do not identify a major change in consensus ratings or price targets. Brokerage Views on CRISPR Therapeutics
• Neutral Sentiment: Manufacturing leadership added: CRISPR appointed Siva Sakhamuri, Ph.D., as chief technical officer. His experience in biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticles may support commercialization, but the appointment is unlikely to materially affect near-term earnings. CRISPR Therapeutics CTO Appointment
• Negative Sentiment: Quarterly results missed expectations: CRISPR reported a third-quarter loss of $1.15 per share versus the roughly $1.04 analyst consensus, while revenue of $12.67 million fell short of estimates near $14.75 million. The company remains deeply unprofitable and continues to depend heavily on its cash reserves to fund its costly development pipeline. CRISPR Therapeutics Earnings Flash

About CRISPR Therapeutics

CRISPR Therapeutics AG NASDAQ: CRSP is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company's research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.